BRD2 and ovarian carcinoma: Recent studies revealed that follicle-stimulating hormone (FSH)-stimulated glycolysis in ovarian malignancy comprised a higher level of the poor prognostic factor ACTL6A, which forecasted metastasis and prognosis of ovarian cancer patients (Chen et al., 2023).